Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

How Goldman Sachs’ life sciences strategy aims to scale private biotechs

Recent investment in Alterome is one of six since 2022 intended to allow biotechs to reach milestones while staying private longer

By Paul Bonanos, Director of Biopharma Intelligence
April 10, 2024 11:23 PM UTC

Editor in Chief Simone Fishburn selected this story as one of BioCentury's Best of 2024. To see the full list, click here.

Goldman Sachs’ investment in oncology company Alterome is the latest new deal from a strategy intended to position the firm’s portfolio companies to scale while still private, navigating a changing environment for biotechs as public markets’ expectations evolve...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Alterome Therapeutics Inc.

Goldman Sachs & Co. LLC